扬农化工(600486) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥2,207,122,043.97, a decrease of 37.60% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥236,971,877.85, an increase of 91.37% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥222,172,745.00, with a year-on-year decrease of 2.40%[4] - Basic earnings per share for Q3 2023 was ¥0.578, a decrease of 17.18% year-on-year[5] - Total operating revenue for the first three quarters of 2023 was CNY 9,273,686,653.08, a decrease of 29.0% compared to CNY 13,102,278,683.72 in the same period of 2022[19] - Net profit for the first three quarters of 2023 was CNY 1,361,553,318.47, a decrease of 16.9% compared to CNY 1,639,422,501.84 in the same period of 2022[21] - Earnings per share for the first three quarters of 2023 were CNY 3.368, down from CNY 4.067 in the same period of 2022[22] - The total comprehensive income for the first three quarters of 2023 was CNY 1,379,593,545.71, down from CNY 1,655,282,803.97 in the same period of 2022[22] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was ¥3,625,082,763.34, an increase of 26.72% compared to the same period last year[4] - The net cash flow from operating activities for the first three quarters of 2023 was CNY 3,625,082,763.34, an increase of 26.7% compared to CNY 2,860,629,467.88 in the same period of 2022[24] - Total cash inflow from operating activities was CNY 10,034,666,125.11, down 23.4% from CNY 13,051,492,245.86 year-on-year[24] - Cash outflow from operating activities totaled CNY 6,409,583,361.77, a decrease of 37.3% compared to CNY 10,190,862,777.98 in the previous year[24] - The net cash flow from investing activities was -CNY 3,409,873,587.47, worsening from -CNY 836,397,969.02 in the same period last year[25] - Cash outflow from investing activities reached CNY 3,416,909,306.01, significantly higher than CNY 853,993,699.75 in the previous year[25] - Cash inflow from financing activities was CNY 690,890,970.00, compared to CNY 247,263,129.49 in the same period of 2022[25] - The net cash flow from financing activities was -CNY 281,754,756.43, slightly improved from -CNY 325,416,650.14 year-on-year[25] - The ending balance of cash and cash equivalents was CNY 2,113,898,618.58, down from CNY 3,733,448,276.72 at the end of the previous year[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥15,505,569,660.17, an increase of 4.81% from the end of the previous year[5] - The company's equity attributable to shareholders was ¥9,516,880,215.59, reflecting an increase of 11.50% year-on-year[5] - Current assets totaled ¥9,613,135,948.85, compared to ¥9,301,996,341.23 at the end of 2022, indicating a growth of approximately 3.34%[12] - Total liabilities as of the end of Q3 2023 were CNY 5,983,328,162.20, a decrease from CNY 6,254,008,274.07 at the end of Q3 2022[22] - Total current liabilities decreased to ¥5,472,785,195.52 from ¥5,761,277,121.56, a decrease of approximately 5.02%[16] - The company's short-term borrowings increased to ¥555,966,666.67 from ¥300,220,000.00, an increase of about 85.00%[16] - Non-current assets totaled ¥5,892,433,711.32, up from ¥5,491,467,278.58, indicating an increase of approximately 7.30%[16] Shareholder Information - As of September 30, 2023, the total number of ordinary shareholders was 19,924, with the top ten shareholders holding a combined 70.69% of shares[8] - The largest shareholder, Syngenta Group Co., Ltd., holds 145,710,256 shares, representing 35.86% of the total[8] Inventory and Receivables - The company reported a significant increase in accounts receivable financing by 134.33% due to the peak season for pesticide sales[7] - Inventory decreased by 37.33% as a result of sales during the peak season[7] - Accounts receivable decreased to ¥2,156,745,587.58 from ¥2,664,648,349.62, a reduction of approximately 19.01%[13] - Inventory decreased significantly to ¥1,306,348,613.95 from ¥2,084,484,094.47, reflecting a decline of about 37.31%[13] Research and Development - Research and development expenses for the first three quarters of 2023 were CNY 301,369,285.62, down from CNY 376,666,871.87 in the same period of 2022[19]